Delivery Order SPE2DB24D2102-SPE2DB24FJHWH

Award Date 9/25/24
Potential Completion Date 9/26/24
Potential Value $8.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, at a ceiling value of $5,054.88. The contract has an ultimate completion date of January 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine, to support federal healthcare programs. The contract has a ceiling value of $8,564.12 and a completion date of June 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $18,394.08 and an ultimate completion date of August 11, 2023. The contract is a firm fixed-price delivery order that does not have a set-aside designation, indicating open competition....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract is a firm fixed-price delivery order with a ceiling value of $4,212.40 and a period of performance through April 2025. The contract is not set aside and is open to full and open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has a ceiling value of $40,781.00 and a completion date of December 3, 2024. It is a firm fixed-price, Delivery Order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $17,639.40. The contract is a firm fixed-price delivery order, with a performance period ending on May 1, 2025. This order is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $4,212.40. The contract is a firm fixed-price delivery order with an ultimate completion date of April 10, 2025. No set-aside was used for this award. AmerisourceBergen holds a larger $999,999,999...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract has a ceiling value of $9,268.12 and a period of performance through February 14, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a larger...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $8,424.80. The contract is a firm fixed-price delivery order with an ultimate completion date of April 28, 2025. The contract was not set aside and is open to full and open competition. AmerisourceBergen Drug Corp holds a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award has a ceiling value of $4,615.50 and an ultimate completion date of May 23, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and...
  • SPE2DB24D2102
    Indefinite Delivery Contract
  • SPE2DB24D2102-SPE2DB24FJHWH
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $8,939.05 and a completion date of September 26, 2024. As a delivery order contract, it is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. This contract does not have a set-aside designation.

Generated 12/25/24, 9:01 AM